You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
|
|---|---|
| Published in |
BMC Cancer, April 2014
|
| DOI | 10.1186/1471-2407-14-258 |
| Pubmed ID | |
| Authors |
Giles W Robinson, Brent A Orr, Amar Gajjar |
| Abstract |
Standard therapies for high grade glioma have failed to substantially improve survival and are associated with significant morbidity. At relapse, high grade gliomas, such as glioblastoma multiforme, are refractory to therapy and universally fatal. BRAF V600E-mutations have been described in a modest 6% to 7% of primary central nervous system (CNS) tumors, but with increased prevalence in the pediatric population and in certain brain tumor subtypes. The use of BRAF inhibitors have transformed melanoma therapy however their use in brain tumors remains unproven. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 33% |
| Italy | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Scientists | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 117 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | <1% |
| Spain | 1 | <1% |
| United States | 1 | <1% |
| Philippines | 1 | <1% |
| Unknown | 113 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 19 | 16% |
| Student > Ph. D. Student | 17 | 15% |
| Student > Master | 13 | 11% |
| Student > Bachelor | 13 | 11% |
| Student > Postgraduate | 12 | 10% |
| Other | 24 | 21% |
| Unknown | 19 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 51 | 44% |
| Biochemistry, Genetics and Molecular Biology | 12 | 10% |
| Agricultural and Biological Sciences | 12 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 6% |
| Neuroscience | 5 | 4% |
| Other | 8 | 7% |
| Unknown | 22 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 January 2016.
All research outputs
#14,194,875
of 22,753,345 outputs
Outputs from BMC Cancer
#3,354
of 8,275 outputs
Outputs of similar age
#120,328
of 226,854 outputs
Outputs of similar age from BMC Cancer
#60
of 140 outputs
Altmetric has tracked 22,753,345 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,275 research outputs from this source. They receive a mean Attention Score of 4.3. This one has gotten more attention than average, scoring higher than 56% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 226,854 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 140 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.